Small-molecule therapeutics for the treatment of glycolipid lysosomal storage disorders

Philosophical Transactions of the Royal Society B: Biological Sciences

Volumn 358, Issue 1433, 2003, Pages 927-945

  Butters, Terry D ^a   Mellor, Howard R ^a   Narita, Keishi ^a   Dwek, Raymond A ^a   Platt, Frances M ^a  

^a UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

Ceramide glucosyltransferase structure; Gaucher disease; Iminosugar inhibitors; Neuropathogenic lysosomal disorders

Indexed keywords

BIOCHEMISTRY;

ANIMALIA; EUKARYOTA;

EID: 0038777078     PISSN: 09628436     EISSN: None     Source Type: Journal    
DOI: 10.1098/rstb.2003.1278     Document Type: Conference Paper

References (62)

1. Abe, A., Radin, N. S. & Shayman, J. A. 1996 Induction of glucosylceramide synthase by synthase inhibitors and ceramide. Biochim. Biophys. Acta 1299, 333-341.
2. Andersson, U., Butters, T. D., Dwek, R. A. & Platt, F. M. 2000 N-Butyldeoxygalactonojirimycin: a more selective inhibitor of glycosphingolipid biosynthesis than N-butyl-deoxynojirimycin, in vitro and in vivo. Biochem. Pharmacol. 59, 821-829.
3. Basu, S., Kaufman, B. & Roseman, S. 1973 Enzymatic synthesis of glucocerebroside by a glucosyltransferase from embryonic chicken brain. J. Biol. Chem. 248, 1388-1394.
4. Bia, J. & Pagano, R. E. 1997 Measurement of spontaneous transfer and transbilayer movement of BODIPY-labelled lipids in lipid vesicles. Biochemistry 36, 8840-8848.
5. Bieberich, E., Freischutz, B., Suzuki, M. & Yu, R. K. 1999 Differential effects of glycolipid biosynthesis inhibitors on ceramide-induced cell death in neuroblastoma cells. J. Neurochem. 72, 1040-1049.
6. Block, T. M., Lu, X. Y., Mehta, A. S., Blumberg, B. S., Tennant, B., Ebling, M., Korba, B., Lansky, D. M., Jacob, G. S. & Dwek, R. A. 1998 Treatment of chronic hepadna-virus infection in a woodchuck animal model with an inhibitor of protein folding and trafficking. Nature Med. 4, 610-614.
7. Bollen, M. & Stalmans, W. 1989 The antiglycogenolytic action of 1-deoxynojirimycin results from a specific inhibition of the alpha-1,6-glucosidase activity of the debranching enzyme. Eur. J. Biochem. 181, 775-780.
8. Booth, P. J. & Curran, A. R. 1999 Membrane protein folding. Curr. Opin. Struct. Biol. 9, 115-121.
9. Borst, P., Zelcer, N. & Van Helvoort, A. 2000 ABC transporters in lipid transport. Biochim. Biophys. Acta 1486, 128-144.
10. Busch, C., Hofmann, F., Selzer, J., Munro, S., Jeckel, D. & Aktories, K. 1998 A common motif of eukaryotic glycosyl-transferases is essential for the enzyme activity of large clostridial cytotoxins. J. Biol. Chem. 273, 19 566-19 572.
11. Butters, T. D., Dwek, R. A. & Platt, F. M. 2000a Inhibition of glycosphingolipid biosynthesis: application to lysosomal storage disorders. Chem. Rev. 100, 4683-4696.
12. Butters, T. D., Van den Broek, L. A. G. M., Fleet, G. W. J., Krulle, T. M., Wormald, M. R., Dwek, R. A. & Platt, F. M. 2000b Molecular requirements of imino sugars for the selective control of N-linked glycosylation and glycosphingolipid biosynthesis. Tetrahedron: Asymmetry 11, 113-124.
13. Campbell, R. E., Mosimann, S. C., Van De Rijn, I., Tanner, M. E. & Strynadka, N. C. 2000 The first structure of UDP-glucose dehydrogenase reveals the catalytic residues necessary for the two-fold oxidation. Biochemistry 39, 7012-7023.
14. Charnock, S. J. & Davies, G. J. 1999 Structure of the nucleotide-diphospho-sugar transferase, SpsA from Bacillus subtilis, in native and nucleotide-complexed forms. Biochemistry 38, 6380-6385.
15. Chester, M. A. 1999 IUPAC-IUB Joint Commission on Biochemical Nomenclature (JCBN) - nomenclature of glycolipids - recommendations 1997. Glycoconjugate J. 16, 1-6.
16. Cox, T. (and 12 others) 2000 Novel oral treatment of Gaucher's disease with N-butyldeoxynojirimycin (OGT 918) to decrease substrate biosynthesis. Lancet 355, 1481-1485.
17. Durantel, D., BranzaNichita, N., CarroueeDurantel, S., Butters, T. D., Dwek, R. A. & Zitzmann, N. 2001 Study of the mechanism of antiviral action of iminosugar derivatives against bovine viral diarrhea virus. J. Virol. 75, 8987-8998.
18. Dwek, R. A., Butters, T. D., Platt, F. M. & Zitzmann, N. 2002 Targeting glycosylation as a therapeutic approach. Nature Rev. Drug Discovery 1, 65-75.
19. Fischer, P. B., Karlsson, G. B., Butters, T. D., Dwek, R. A. & Platt, F. M. 1996 N-butyldeoxynojirimycin-mediated inhibition of human immunodeficiency virus entry correlates with changes in antibody recognition of the V1/V2 region of gp120. J. Virol. 70, 7143-7152.
20. 3. J. Acquired Immune Deficiency Syndrome 7, 139-147.
21. Furst, W. & Sandhoff, K. 1992 Activator proteins and topology of lysosomal sphingolipid catabolism. Biochim. Biophys. Acta 1126, 1-16.
22. Gastinel, L. N., Cambillau, C. & Bourne, Y. 1999 Crystal structures of the bovine beta4galactosyltransferase catalytic domain and its complex with uridine diphosphogalactose. EMBO J. 18, 3546-3557.
23. Goss, P. E., Reid, C. L., Bailey, D. & Dennis, J. W. 1997 Phase IB clinical trial of the oligosaccharide processing inhibitor swainsonine in patients with advanced malignancies. Clin. Cancer Res. 3, 1077-1086.
24. Ha, S., Walker, D., Shi, Y. & Walker, S. 2000 The 1.9 A crystal structure of Escherichia coli MurG, a membrane-associated glycosyltransferase involved in peptidoglycan biosynthesis. Protein Sci. 9, 1045-1052.
25. Heinrich, M., Wickel, M., Schneider-Brachert, W., Sandberg, C., Gahr, J., Schwandner, R., Brunner, J., Kronke, M. & Schutze, S. 1999 Cathepsin D targeted by acid sphingomyelinase-derived ceramide. EMBO J. 18, 5252-5263.
26. Ichikawa, S., Sakiyama, H., Suzuki, G., Kazuya, I.-P., Hidari, J. & Hirabayashi, Y. 1996 Expression cloning of a cDNA for human ceramide glucosyltransferase that catalyses the first glycosylation step of glycosphingolipid synthesis. Proc. Natl Acad. Sci. USA 93, 4638-4643.
27. Jeyakumar, M., Butters, T. D., CortinaBorja, M., Hunnam, V., Proia, R. L., Perry, V. H., Dwek, R. A. & Platt, F. M. 1999 Delayed symptom onset and increased life expectancy in Sandhoff disease mice treated with N-butyldeoxynojirimycin. Proc. Natl Acad. Sci. USA 96, 6388-6393.
28. Kapitonov, D. & Yu, R. K. 1999 Conserved domains of glycosyltransferases. Glycobiology 9, 961-978.
29. Kolter, T. & Sandhoff, K. 1999 Sphingolipids - their metabolic pathways and the pathobiochemistry of neurodegenerative diseases. Angew. Chem. Int. Ed. 38, 1532-1568.
30. Komori, H., Ichikawa, S., Hirabayashi, Y. & Ito, M. 2000 Regulation of UDP-glucose:ceramide glucosyltransferase-1 by ceramide. FEBS Lett. 475, 247-250.
31. Kronke, M. 1999 Biophysics of ceramide signaling: interaction with proteins and phase transition of membranes. Chem. Phys. Lipids 101, 109-121.
32. Lachmann, R. H. & Platt, F. M. 2001 Substrate reduction therapy for glycosphingolipid storage disorders. Expert Opin. Invest. Drugs 10, 455-466.
33. le Maire, M., Champeil, P. & Moller, J. V. 2000 Interaction of membrane proteins and lipids with solubilising detergents. Biochim. Biophys. Acta 1508, 86-111.
34. Lipsky, N. G. & Pagano, R. E. 1983 Sphingolipid metabolism in cultured fibroblasts: microscopic and biochemical studies employing a fluorescent ceramide analogue. Proc. Natl Acad. Sci. USA 80, 2608-2612.
35. Mahuran, D. J. 1998 The GM2 activator protein, its roles as a co-factor in GM2 hydrolysis and as a general glycolipid transport protein. Biochim. Biophys. Acta 1393, 1-18.
36. Marks, D. L., Wu, K. J., Paul, P., Kamisaka, Y., Watanabe, R. & Pagano, R. E. 1999 Oligomerization and topology of the Golgi membrane protein glucosylceramide synthase. J. Biol. Chem. 274, 451-456.
37. Mehta, A., Lu, X. Y., Block, T. M., Blumberg, B. S. & Dwek, R. A. 1997 Hepatitis B virus (HBV) envelope glycoproteins vary drastically in their sensitivity to glycan processing: evidence that alteration of a single N-linked glycosylation site can regulate HBV secretion. Proc. Natl Acad. Sci. USA 94, 1822-1827.
38. Meikle, P. J., Hopwood, J. J., Clague, A. E. & Carey, W. F. 1999 Prevalence of lysosomal storage disorders. J. Am. Med. Assoc. 281, 249-254.
39. Mellor, H. R., Nolan, J., Pickering, L., Wormald, M. R., Platt, F. M., Dwek, R. A., Fleet, G. W. J. & Butters, T. D. 2002 Preparation, biochemical characterisation and biological properties of radiolabelled N-alkylated deoxynojirimycins. Biochem. J. 366, 225-233.
40. Mitrakou, A., Tountas, N., Raptis, A. E., Bauer, R. J., Schulz, H. & Raptis, S. A. 1998 Long-term effectiveness of a new alpha-glucosidase inhibitor (BAY m1099-miglitol) in insulin-treated type 2 diabetes mellitus. Diabetic Med. 15, 657-660.
41. Moyses, C. 2003 Substrate reduction therapy: clinical evaluation in type 1 Gaucher disease. Phil. Trans. R. Soc. Lond. B 358, 955-960. (DOI 10.1098/rstb.2003.1271.)
42. Platt, F. M., Neises, G. R., Dwek, R. A. & Butters, T. D. 1994a N-Butyldeoxynojirimycin is a novel inhibitor of glycolipid biosynthesis. J. Biol. Chem. 269, 8362-8365.
43. Platt, F. M., Neises, G. R., Karlsson, G. B., Dwek, R. A. & Butters, T. D. 1994b N-butyldeoxygalactonojirimycin inhibits glycolipid biosynthesis but does not affect N-linked oligosaccharide processing. J. Biol. Chem. 269, 27 108-27 114.
44. Platt, F. M., Neises, G. R., Reinkensmeier, G., Townsend, M. J., Perry, V. H., Proia, R. L., Winchester, B., Dwek, R. A. & Butters, T. D. 1997a Prevention of lysosomal storage in Tay-Sachs mice treated with N-butyldeoxynojirimycin. Science 276, 428-431.
45. Platt, F. M., Reinkensmeier, G., Dwek, R. A. & Butters, T. D. 1997b Extensive glycosphingolipid depletion in the liver and lymphoid organs of mice treated with N-butyldeoxynojirimycin. J. Biol. Chem. 272, 19 365-19 372.
46. Platt, F. M., Jeyakumar, M., Andersson, U., Heare, T., Dwek, R. A. & Butters, T. D. 2003 Substrate reduction therapy in mouse models of the glycosphingolipidoses. Phil. Trans. R. Soc. Lond. B 358, 947-954. (DOI 10.1098/rstb.2003.1279.)
47. Priestman, D. A., Platt, F. M., Dwek, R. A. & Butters, T. D. 2000 Imino sugar therapy for type I Gaucher disease. Glycobiology 10, iv-vi.
48. Sandhoff, K. & Kolter, T. 2003 Biosynthesis and degradation of mammalian glycosphingolipids. Phil. Trans. R. Soc. Lond. B 358, 847-861. (DOI 10.1098/rstb.2003.1265.)
49. Stahl, N., Jurevics, H., Morell, P., Suzuki, K. & Popko, B. 1994 Isolation, characterization, and expression of cDNA clones that encode rat UDP-galactose:ceramide galactosyl-transferase. J. Neurosci. Res. 38, 234-242.
50. Tan, A., Van den Broek, L., Bolscher, J., Vermaas, D. J., Pastoors, L., Van Boeckel, C. & Ploegh, H. 1994 Introduction of oxygen into the alkyl chain of N-decyl-dNM decreases lipophilicity and results in increased retention of glucose residues on N-linked oligosaccharides. Glycobiology 4, 141-149.
51. Unligil, U. M., Zhou, S., Yuwaraj, S., Sarkar, M., Schachter, H. & Rini, J. M. 2000 X-ray crystal structure of rabbit N-acetylglucosaminyltransferase I: catalytic mechanism and a new protein superfamily. EMBO J. 19, 5269-5280.
52. Van Asselt, E. J., Thunnissen, A. M. & Dijkstra, B. W. 1999 High resolution crystal structures of the Escherichia coli lytic transglycosylase Slt70 and its complex with a peptidoglycan fragment. J. Mol. Biol. 291, 877-898.
53. Vrielink, A., Ruger, W., Driessen, H. P. & Freemont, P. S. 1994 Crystal structure of the DNA modifying enzyme beta-glucosyltransferase in the presence and absence of the substrate uridine diphosphoglucose. EMBO J. 13, 3413-3422.
54. Watson, A. A., Fleet, G. W. J., Asano, N., Molyneux, R. J. & Nash, R. J. 2001 Polyhydroxylated alkaloids - natural occurrence and therapeutic applications. Phytochemistry 56, 265-295.
55. Wiggins, C. A. & Munro, S. 1998 Activity of the yeast MNN1 alpha-1,3-mannosyltransferase requires a motif conserved in many other families of glycosyltransferases. Proc. Natl Acad. Sci. USA 95, 7945-7950.
56. Wright, C. S., Li, S. C. & Rastinejad, F. 2000 Crystal structure of human GM2-activator protein with a novel beta-Cup topology. J. Mol. Biol. 304, 411-422.
57. Wu, K., Marks, D. L., Watanabe, R., Paul, P., Rajan, N. & Pagano, R. E. 1999 Histidine-193 of rat glucosylceramide synthase resides in a UDP-glucose- and inhibitor (D-threo-1-phenyl-2-decanoylamino-3-morpholinopropan-1-ol)-binding region: a biochemical and mutational study. Biochem. J. 341, 395-400.
58. Yamashita, T., Wada, R., Sasaki, T., Deng, C. X., Bierfreund, U., Sandhoff, K. & Proia, R. L. 1999 A vital role for glycos-phingolipid synthesis during development and differentiation. Proc. Natl Acad. Sci. USA 96, 9142-9147.
59. Zimran, A. & Elstein, D. 2003 Gaucher disease and the clinical experience with substrate reduction therapy. Phil. Trans. R. Soc. Lond. B 358, 961-966. (DOI 10.1098/rstb.2003.1272.)
60. Zhong, Q., Husslein, T., Moore, P. B., Newns, D. M., Pattnaik, P. & Klein, M. L. 1998 The M2 channel of influenza A virus: a molecular dynamics study. FEBS Lett. 434, 265-271.
61. Zhong, Q., Newns, D. M., Pattnaik, P., Lear, J. D. & Klein, M. L. 2000 Two possible conducting states of the influenza A virus M2 ion channel. FEBS Lett. 473, 195-198.
62. Zitzmann, N., Mehta, A. S., Carrouee, S., Butters, T. D., Platt, F. M., McCauley, J., Blumberg, B. S., Dwek, R. A. & Block, T. M. 1999 Imino sugars inhibit the formation and secretion of bovine viral diarrhea virus, a pestivirus model of hepatitis C virus: implications for the development of broad spectrum anti-hepatitis virus agents. Proc. Natl Acad. Sci. USA 96, 11 878-11 882.